RU2019137737A - METHOD FOR PREVENTION AND TREATMENT OF PUMPING AND MEANS FOR PREVENTION AND TREATMENT OF PUMPING (VERSIONS) - Google Patents

METHOD FOR PREVENTION AND TREATMENT OF PUMPING AND MEANS FOR PREVENTION AND TREATMENT OF PUMPING (VERSIONS) Download PDF

Info

Publication number
RU2019137737A
RU2019137737A RU2019137737A RU2019137737A RU2019137737A RU 2019137737 A RU2019137737 A RU 2019137737A RU 2019137737 A RU2019137737 A RU 2019137737A RU 2019137737 A RU2019137737 A RU 2019137737A RU 2019137737 A RU2019137737 A RU 2019137737A
Authority
RU
Russia
Prior art keywords
morpholinoethylthio
triazino
indole
dihydrochloride monohydrate
active substance
Prior art date
Application number
RU2019137737A
Other languages
Russian (ru)
Other versions
RU2753952C2 (en
RU2019137737A3 (en
Inventor
Владимир Леонидович Пастушенков
Виктор Иванович Герасимов
Лев Александрович Глазников
Александр Леонидович Пастушенков
Original Assignee
Общество с ограниченной ответственностью «Фарм-ТРИСАН»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью «Фарм-ТРИСАН» filed Critical Общество с ограниченной ответственностью «Фарм-ТРИСАН»
Priority to RU2019137737A priority Critical patent/RU2753952C2/en
Priority to PCT/RU2020/000624 priority patent/WO2021101409A2/en
Publication of RU2019137737A publication Critical patent/RU2019137737A/en
Publication of RU2019137737A3 publication Critical patent/RU2019137737A3/ru
Application granted granted Critical
Publication of RU2753952C2 publication Critical patent/RU2753952C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1. Способ профилактики укачивания, в котором используют препарат группы антигипоксантов за 3 дня до ожидаемой вестибулярной нагрузки, отличающийся тем, что в качестве препарата антигипоксанта используют препарат на основе активного вещества дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола.1. A method for the prevention of motion sickness, in which a preparation of the group of antihypoxants is used 3 days before the expected vestibular load, characterized in that the preparation based on the active substance dihydrochloride monohydrate 3- (2-morpholinoethylthio) -1,2,4- is used as the antihypoxant preparation. triazino [5,6-b] indole. 2. Способ по п.1, отличающийся тем, что активное вещество дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола вводят одноразово в дозировке от 3,4 до 6,7 мг/кг в виде инъекции композиции в растворе натрия хлорида, смешанного с водой, содержащее NaOH при следующем соотношении массовой концентрации ингредиентов, г/л:2. The method according to claim 1, characterized in that the active substance dihydrochloride monohydrate 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b] indole is administered once in a dosage of 3.4 to 6, 7 mg / kg in the form of an injection of the composition in a solution of sodium chloride mixed with water, containing NaOH at the following ratio of the mass concentration of the ingredients, g / l: дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)3- (2-morpholinoethylthio) dihydrochloride monohydrate -1,2,4-триазино[5,6-b] индола-1,2,4-triazino [5,6-b] indole 9,5-10,59.5-10.5 натрий хлоридsodium chloride 6,0-9,06.0-9.0 NaOHNaOH 0,2-1,00.2-1.0 водаwater остальноеrest
3. Способ по п.1, отличающийся тем, что активное вещество дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола используют в виде таблеток, которые применяют перорально внутрь за 3 дня до ожидаемой вестибулярной нагрузки и однократно за 1,5 часа непосредственно до укачивания.3. The method according to claim 1, characterized in that the active substance dihydrochloride monohydrate 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b] indole is used in the form of tablets, which are administered orally by mouth for 3 days before the expected vestibular load and once for 1.5 hours immediately before motion sickness. 4. Способ лечения укачивания, в котором используют препарат группы антигипоксантов, отличающийся тем, что в качестве препарата антигипоксанта используют препарат на основе активного вещества дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола, который вводят одноразово в дозировке от 3,4 до 6,7 мг/кг в виде инъекции композиции в растворе натрия хлорида, смешанного с водой, периодически повторяя эту процедуру через 1 месяц до полного устранения симпотомов укачивания.4. A method for the treatment of motion sickness, in which a preparation of the group of antihypoxants is used, characterized in that the preparation based on the active substance dihydrochloride monohydrate 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b ] indole, which is administered once at a dosage of 3.4 to 6.7 mg / kg as an injection of the composition in a solution of sodium chloride mixed with water, periodically repeating this procedure after 1 month until the symptoms of motion sickness are completely eliminated. 5. Способ по п.4, отличающийся тем, что активное вещество дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола используют в виде таблеток, которые применяют перорально внутрь в течение года.5. The method according to claim 4, characterized in that the active substance 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b] indole dihydrochloride monohydrate is used in the form of tablets, which are administered orally during of the year. 6. Способ по п.4, отличающийся тем, что препарат на основе активного вещества дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола вводят одноразово в дозировке от 3,4 до 6,7 мг/кг в виде инъекции композиции в растворе натрия хлорида, смешанного с водой, содержащего NaOH при следующем соотношении массовой концентрации ингредиентов, г/л:6. The method according to claim 4, characterized in that the preparation based on the active substance 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b] indole dihydrochloride monohydrate is administered once in a dosage of 3.4 up to 6.7 mg / kg in the form of an injection of the composition in a solution of sodium chloride mixed with water containing NaOH at the following ratio of the mass concentration of the ingredients, g / l: дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)3- (2-morpholinoethylthio) dihydrochloride monohydrate -1,2,4-триазино[5,6-b] индола-1,2,4-triazino [5,6-b] indole 9,5-10,59.5-10.5 натрий хлоридsodium chloride 6,0-9,06.0-9.0 NaOHNaOH 0,2-1,00.2-1.0 водаwater остальноеrest
7. Средство для профилактики и лечения укачивания, полученное в форме композиции, содержащей в качестве активного вещества дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола в растворе натрия хлорида, смешанного с водой, отличающееся тем, что композиция лекарственного средства выполнена pH от 4,8 до 5,8, с динамической вязкостью 1,08 мм2/с при комнатной температуре 20°С, а физ.раствор при той же температуре имеет общую плотность композиции 1,010 г/см3. 7. An agent for the prevention and treatment of motion sickness, obtained in the form of a composition containing 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b] indole dihydrochloride monohydrate as an active substance in a solution of sodium chloride mixed with water, characterized in that the drug composition is made with a pH of 4.8 to 5.8, with a dynamic viscosity of 1.08 mm 2 / s at a room temperature of 20 ° C, and a saline solution at the same temperature has a total density of the composition 1.010 g / cm 3 . 8. Средство для профилактики и лечения укачивания, полученное в форме таблетки, содержащей в качестве активного вещества дигидрохлорид моногидрат 3-(2-морфолиноэтилтио)-1,2,4-триазино[5,6-b]индола, а также вспомогательные вещества и консерванты, заключенные в желатиновую оболочку. 8. An agent for the prevention and treatment of motion sickness, obtained in the form of a tablet containing 3- (2-morpholinoethylthio) -1,2,4-triazino [5,6-b] indole dihydrochloride monohydrate as an active substance, as well as auxiliary substances and preservatives enclosed in a gelatinous shell.
RU2019137737A 2019-11-22 2019-11-22 Method for preventing and treating motion sickness and agent for preventing and treating motion sickness (variants) RU2753952C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2019137737A RU2753952C2 (en) 2019-11-22 2019-11-22 Method for preventing and treating motion sickness and agent for preventing and treating motion sickness (variants)
PCT/RU2020/000624 WO2021101409A2 (en) 2019-11-22 2020-11-20 Method for preventing and treating motion sickness, and agent for preventing and treating motion sickness (variants)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019137737A RU2753952C2 (en) 2019-11-22 2019-11-22 Method for preventing and treating motion sickness and agent for preventing and treating motion sickness (variants)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021122935A Division RU2021122935A (en) 2021-08-02 MEANS FOR PREVENTION OF MOSCOW (OPTIONS)

Publications (3)

Publication Number Publication Date
RU2019137737A true RU2019137737A (en) 2021-05-24
RU2019137737A3 RU2019137737A3 (en) 2021-05-24
RU2753952C2 RU2753952C2 (en) 2021-08-24

Family

ID=75981414

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019137737A RU2753952C2 (en) 2019-11-22 2019-11-22 Method for preventing and treating motion sickness and agent for preventing and treating motion sickness (variants)

Country Status (2)

Country Link
RU (1) RU2753952C2 (en)
WO (1) WO2021101409A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414895A1 (en) * 1989-03-13 1991-03-06 Nauchno-Proizvodstvennoe Obiedinenie "Biolar" OROTATE OF $g(a)-AMINO-$g(b)-PHENYL-BUTYRIC ACID
RU2119335C1 (en) * 1997-12-25 1998-09-27 Пастушенков Леонид Васильевич Agent for treatment of patients with acute and sudden sensoneural diminished hearing and deafness
RU2008106419A (en) * 2008-02-21 2009-08-27 Закрытое акционерное общество "Ива фарм" (RU) MEDICINES BASED ON OLIGO-NUCLEAR COORDINATION COMPOUNDS OF D-METALS, METHOD FOR THERAPEUTIC INFLUENCE ON THE PATIENT'S ORGANISM AND METHOD FOR IMPROVING THERAPEUTIC EFFICIENCY OF PHARMACOLOGY

Also Published As

Publication number Publication date
WO2021101409A2 (en) 2021-05-27
RU2753952C2 (en) 2021-08-24
WO2021101409A3 (en) 2021-07-15
RU2019137737A3 (en) 2021-05-24

Similar Documents

Publication Publication Date Title
CN1108153C (en) Oral compositions containing ondansetron
US20190000842A1 (en) Treating Sexual Desire Disorders with Flibanserin
Abaza et al. Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: a report on 546 patients in Egypt
RU2002106399A (en) MOXIFLOXACIN COMPOSITIONS CONTAINING SODIUM SALT
BG99700A (en) Application of 2-amino-6-n-propylamino-4,5,6,7-tetraydrobenzothiazole as pharmaceutical composition of antidepressive effect
RU2009126616A (en) POWDER VALGANTSIKLOVIR
CN1314396C (en) Application of levoornidazole in preparation of anti anaerobic bacteria infection medicine
EA001878B1 (en) Method for treatment of bacterial infection in children
RU2019137737A (en) METHOD FOR PREVENTION AND TREATMENT OF PUMPING AND MEANS FOR PREVENTION AND TREATMENT OF PUMPING (VERSIONS)
UA73316C2 (en) Pharmaceutical formulations containing benzamide derivative as active ingredient
RU2021122935A (en) MEANS FOR PREVENTION OF MOSCOW (OPTIONS)
RU2725622C1 (en) Pharmaceutical composition for treating and/or preventing liver diseases
RU2003100081A (en) METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY
CN114788817A (en) Diphenhydramine pharmaceutical composition
US20140275138A1 (en) Method and products for treating diabetes
RU2464984C2 (en) Non-steroid anti-inflammatory drug
RU2780141C1 (en) Preparation for the treatment of dogs with trichomoniasis, giardiasis, amoebiasis and toxocarosis
EP2874603B1 (en) Glucosaline maintenance solution for pediatric parenteral administration
RU2005104747A (en) THE DRUG FOR THE TREATMENT OF POST-UNIVERSAL PURULAR-CATARAL ENDOMETRITIS AND MASTITIS IN COWS AND METHODS OF ITS APPLICATION
CN114557992A (en) Application of compound pharmaceutical composition in preparation of medicine for treating interstitial pneumonia
RU2022107184A (en) USE OF 1-(2-(1H-IMIDAZOL-4-YL)ETHYL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF COUGH CAUSED BY VIRAL INFECTIONS
RU2751351C2 (en) Oral ibuprofen medication
SU533323A3 (en) Method for enhancing biological activity of α-oxitriptophan
RU2276979C2 (en) Pharmaceutical composition with anti-diarrhea effect
KR101808963B1 (en) Stability improved composite particles containing fesoterodine fumarate and oral dosage form comprising the same